Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

Recruiting

Phase 2

Autologous Cell TherapySafety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

Sponsor:

VivaTech International, Inc.

Code:

NCT02844751

Conditions

Osteoarthritis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

[StroMed + platelet rich plasma (PRP)]

[PRP] platelet rich plasma

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-19. This information was provided to ClinicalTrials.gov by VivaTech International, Inc. on 2025-10-14.